We’ve gone through blood, sweat, and tears to get here. This validates everything we’ve built,' Saldanha said.

AbbVie partners with IGI Therapeutics for ISB 2001, a potential cancer and autoimmune therapy. Read more here.

IGI Therapeutics SA, a wholly-owned subsidiary of Ichnos Glenmark Innovation (IGI)—an alliance between Glenmark Pharma and Ichnos Sciences Inc.—has signed an exclusive licensing agreement with AbbVie ...

AbbVie Inc. (NYSE:ABBV) saw its stock jump 3.4% after announcing a major licensing agreement with IGI Therapeutics, securing ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

The global Monoclonal Antibodies Market was valued at USD 186 Billion in 2021 and is projected to exhibit a CAGR of 12% from ...